AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2674064 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid-crystal-contact-thermography (LCCT)
Number of subjects: 300
Study 31908300 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel plus carboplatin
Number of subjects: 0
Study 31908300 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30921176 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching chest compression first (Group 2)
Number of subjects: 95
Study 30921176 — intervention group
Group type: COMPARATOR
Intervention: Standard CPR training (Group 1)
Number of subjects: 95
Study 28842139 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose daunorubicin (90 mg/m2 on days 1-3) and cytosine arabinoside (200 mg/m2/day continuous infusion on days 1-7)
Number of subjects: 26
Study 28842139 — intervention group
Group type: COMPARATOR
Intervention: Low-dose daunorubicin (45 to 60 mg/m2)
Number of subjects: 26
Study 25373684 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Teen Triple P (GTTP)
Number of subjects: 72
Study 25373684 — intervention group
Group type: COMPARATOR
Intervention: care as usual (CAU)
Number of subjects: 72
Study 23859487 — intervention group
Group type: EXPERIMENTAL
Intervention: Red orange juice
Number of subjects: 17
Study 23859487 — intervention group
Group type: EXPERIMENTAL
Intervention: Blond orange juice
Number of subjects: 17
Study 22586902 — intervention group
Group type: EXPERIMENTAL
Intervention: cycloferon suppositoria
Number of subjects: 126
Study 22586902 — intervention group
Group type: EXPERIMENTAL
Intervention: intramuscular cycloferon
Number of subjects: 126
Study 22586902 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 126
Study 19370543 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine 0.12% mouthrinse
Number of subjects: 55
Study 19370543 — intervention group
Group type: EXPERIMENTAL
Intervention: Lippia sidoides essential oil 1% mouthrinse
Number of subjects: 55
Study 16618855 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser group (laser-guided collimator)
Number of subjects: 18
Study 16618855 — intervention group
Group type: COMPARATOR
Intervention: Non-laser group (conventional rectangular collimator)
Number of subjects: 18
Study 15871639 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous imipenem 1g plus cilastatin 1g
Number of subjects: 20
Study 15871639 — intervention group
Group type: COMPARATOR
Intervention: Intravenous meropenem 1g
Number of subjects: 20
Study 11684937 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent condom use
Number of subjects: 17264
Study 11684937 — intervention group
Group type: EXPERIMENTAL
Intervention: Irregular condom use
Number of subjects: 17264
Study 9203726 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral poliovirus vaccine (OPV2) administered after recent diarrhea history
Number of subjects: 728
Study 9203726 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral poliovirus vaccine (OPV1, OPV2, OPV3, OPV4)
Number of subjects: 728
Study 9203726 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate models controlling for various factors
Number of subjects: 728
Study 9203726 — intervention group
Group type: EXPERIMENTAL
Intervention: Current recommendation for children with diarrhea to receive OPV and be reimmunized post-illness
Number of subjects: 728
Study 7963412 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant alpha interferon (6 MU x 3/week for 3 months then 3 MU x 3/week for 3 months)
Number of subjects: 75
Study 7963412 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant alpha interferon (3 MU x 3/week for 6 months)
Number of subjects: 75
Study 7963412 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant alpha interferon
Number of subjects: 75
Study 3113995 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin regimen
Number of subjects: 0
Study 3113995 — intervention group
Group type: COMPARATOR
Intervention: Non-rifampicin regimen
Number of subjects: 0
Study 31014200 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate ablation (CAA)
Number of subjects: 400
Study 31014200 — intervention group
Group type: COMPARATOR
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 400
Study 28558104 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-based treatment (PBT)
Number of subjects: 150
Study 28558104 — intervention group
Group type: COMPARATOR
Intervention: Family-based treatment (FBT)
Number of subjects: 150
Study 26006754 — intervention group
Group type: EXPERIMENTAL
Intervention: UMEC/VI 62.5/25 mcg
Number of subjects: 703
Study 26006754 — intervention group
Group type: COMPARATOR
Intervention: FP/SAL 250/50 mcg
Number of subjects: 703
Study 23480875 — intervention group
Group type: COMPARATOR
Intervention: Milk
Number of subjects: 13
Study 23480875 — intervention group
Group type: EXPERIMENTAL
Intervention: Maize porridge plus oil
Number of subjects: 13
Study 23480875 — intervention group
Group type: EXPERIMENTAL
Intervention: Maize porridge
Number of subjects: 13
Study 23480875 — intervention group
Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 13
Study 21952084 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice Outreach Facilitation with regular monthly meetings over a one- to two-year period, including audit and feedback, consensus building, and goal setting.
Number of subjects: 0
Study 21952084 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative analysis of Practice Outreach Facilitators' written narratives of their ongoing practice interactions.
Number of subjects: 0
Study 19307290 — intervention group
Group type: EXPERIMENTAL
Intervention: Head shake modification to the Sensory Organization Test (SOT)
Number of subjects: 91
Study 19307290 — intervention group
Group type: COMPARATOR
Intervention: Standard Sensory Organization Test (SOT)
Number of subjects: 91
Study 16520833 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (1.2 mg/kg)
Number of subjects: 26
Study 16520833 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 26
Study 14995053 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed
Number of subjects: 0
Study 11120566 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of visual pigment genes in mothers of males with congenital color-vision deficiencies
Number of subjects: 146
Study 11120566 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of visual pigment genes in randomly-selected females
Number of subjects: 146
Study 9644632 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with osteitis fibrosa (OF)
Number of subjects: 40
Study 9644632 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with osteomalacia (OM)
Number of subjects: 40
Study 9644632 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with osteitis fibrosa (OF) and osteomalacia (OM)
Number of subjects: 40
Study 9644632 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with renal osteodystrophy
Number of subjects: 40
Study 9644632 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic intervention
Number of subjects: 40
Study 7931010 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg or 6 mg relaxin (rhRlx) gel
Number of subjects: 11
Study 7931010 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 11
Study 2908516 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketazolam
Number of subjects: 0
Study 2908516 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 0
Study 2908516 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 0
Study 2908516 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (challenge dose)
Number of subjects: 0
Study 2908516 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term benzodiazepine use
Number of subjects: 0
Study 31933278 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Fe diet (0 mg/kg Fe)
Number of subjects: 900
Study 31933278 — intervention group
Group type: EXPERIMENTAL
Intervention: M-Fe diet (80 mg/kg Fe)
Number of subjects: 900
Study 31933278 — intervention group
Group type: EXPERIMENTAL
Intervention: H-Fe diet (160 mg/kg Fe)
Number of subjects: 900
Study 31933278 — intervention group
Group type: EXPERIMENTAL
Intervention: Mn sulfate (MnSO4)
Number of subjects: 900
Study 31933278 — intervention group
Group type: EXPERIMENTAL
Intervention: Manganese-lysine chelate (MnLys)
Number of subjects: 900
Study 31933278 — intervention group
Group type: COMPARATOR
Intervention: Control (Fe and Mn unsupplemented diets)
Number of subjects: 900
Study 30699301 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin plus sulfadoxine‐pyrimethamine plus amodiaquine
Number of subjects: 19578
Study 30699301 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus sulfadoxine‐pyrimethamine plus amodiaquine
Number of subjects: 19578
Study 28610675 — intervention group
Group type: EXPERIMENTAL
Intervention: Single moderate-to-severe exacerbation
Number of subjects: 0
Study 28610675 — intervention group
Group type: COMPARATOR
Intervention: Non-exacerbators
Number of subjects: 0
Study 25175757 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% red sorghum pasta (RSP)
Number of subjects: 20
Study 25175757 — intervention group
Group type: COMPARATOR
Intervention: Control pasta (CP)
Number of subjects: 20
Study 23496939 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (home visits and group activities)
Number of subjects: 459
Study 23496939 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 459
Study 21773032 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (ritodrine and magnesium)
Number of subjects: 33
Study 21773032 — intervention group
Group type: COMPARATOR
Intervention: Magnesium alone
Number of subjects: 33
Study 18242069 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower Limb Training Group (LLTG)
Number of subjects: 22
Study 18242069 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper Limb Training Group (ULTG)
Number of subjects: 22
Study 18242069 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 22
Study 17070175 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 20 mg/d for 12 weeks
Number of subjects: 99
Study 17070175 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/d for 12 weeks
Number of subjects: 99
Study 17070175 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Policosanol + Atorvastatin)
Number of subjects: 99
Study 17070175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 12603503 — intervention group
Group type: EXPERIMENTAL
Intervention: AAT deficiency subjects (n=86)
Number of subjects: 114
Study 12603503 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=27)
Number of subjects: 114
Study 12603503 — intervention group
Group type: EXPERIMENTAL
Intervention: AAT deficiency subjects (hyperresponsive)
Number of subjects: 114
Study 12556657 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 9
Study 12556657 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 9
Study 12556657 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive drugs (various classes)
Number of subjects: 9
Study 12556657 — intervention group
Group type: COMPARATOR
Intervention: Untreated control patients
Number of subjects: 9
Study 10827879 — intervention group
Group type: EXPERIMENTAL
Intervention: Involuntary out-patient commitment (OPC) for > or = 6 months
Number of subjects: 262
Study 10827879 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended OPC combined with regular out-patient services, adherence to prescribed medications, and no substance misuse
Number of subjects: 262
Study 10827879 — intervention group
Group type: COMPARATOR
Intervention: Control group (no OPC)
Number of subjects: 262
Study 9025797 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypobaria (barometric pressure of 429 mmHg)
Number of subjects: 0
Study 9025797 — intervention group
Group type: COMPARATOR
Intervention: Normobaric environment (baseline condition)
Number of subjects: 0
Study 1346563 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg)
Number of subjects: 0
Study 1346563 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (120 mg)
Number of subjects: 0
Study 1346563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6743447 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine sulphate 2 mg
Number of subjects: 27
Study 6743447 — intervention group
Group type: EXPERIMENTAL
Intervention: diamorphine hydrochloride 2 mg
Number of subjects: 27
Study 2872740 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy and aspirin therapy
Number of subjects: 500
Study 2872740 — intervention group
Group type: COMPARATOR
Intervention: Aspirin therapy alone
Number of subjects: 500
Study 31691105 — intervention group
Group type: EXPERIMENTAL
Intervention: aPAP + SensAwake (SA)
Number of subjects: 85
Study 31691105 — intervention group
Group type: COMPARATOR
Intervention: aPAP
Number of subjects: 85
Study 29725795 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine with epinephrine 1/200,000
Number of subjects: 37
Study 29725795 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine without epinephrine
Number of subjects: 37
Study 29725795 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 37
Study 29725795 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 37
Study 28629874 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS intervention
Number of subjects: 12
Study 28629874 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS intervention
Number of subjects: 12
Study 28629874 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Hz rTMS intervention
Number of subjects: 12
Study 28629874 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline (before rTMS)
Number of subjects: 12
Study 25691293 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) combined with pegylated interferon alpha-2b (PEG-IFNα-2b)
Number of subjects: 105
Study 25691293 — intervention group
Group type: COMPARATOR
Intervention: Control group (palliative therapy)
Number of subjects: 105
Study 23413910 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled inactivated Mycobacterium phlei
Number of subjects: 0
Study 23413910 — intervention group
Group type: COMPARATOR
Intervention: Inhaled Seretide
Number of subjects: 0
Study 22196620 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein
Number of subjects: 32
Study 22196620 — intervention group
Group type: EXPERIMENTAL
Intervention: Pea protein
Number of subjects: 32
Study 22196620 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey
Number of subjects: 32
Study 22196620 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg albumin
Number of subjects: 32
Study 22196620 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltodextrin
Number of subjects: 32
Study 22196620 — intervention group
Group type: COMPARATOR
Intervention: Water control
Number of subjects: 32
Study 19380258 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 2 mL lignocaine
Number of subjects: 15
Study 19380258 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection of 5% hypertonic saline
Number of subjects: 15
Study 16512941 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dairy product intake (4th quartile vs. 1st)
Number of subjects: 2776
Study 16512941 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher calcium intake (4th quartile vs. 1st)
Number of subjects: 2776
Study 16512941 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental yoghurt consumption (125 g/d)
Number of subjects: 2776
Study 15369611 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-manual social class
Number of subjects: 3187
Study 15369611 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition from manual to non-manual social class
Number of subjects: 3187
Study 15369611 — intervention group
Group type: COMPARATOR
Intervention: Manual social class
Number of subjects: 3187
Study 11503009 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of rifabutin every 7 days (group 1)
Number of subjects: 24
Study 11503009 — intervention group
Group type: COMPARATOR
Intervention: 150 mg of rifabutin every 3 days (group 2)
Number of subjects: 24
Study 11503009 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined groups
Number of subjects: 24
Study 11503009 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 9423997 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact lenses
Number of subjects: 125
Study 9423997 — intervention group
Group type: COMPARATOR
Intervention: Spectacles
Number of subjects: 125
Study 8488716 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vaccine
Number of subjects: 30
Study 8488716 — intervention group
Group type: COMPARATOR
Intervention: Parenteral vaccine
Number of subjects: 30
Study 2441202 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (mean daily dose 84 mg)
Number of subjects: 23
Study 2441202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 29635857 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (1000 mg)
Number of subjects: 24
Study 29635857 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine (50 mg)
Number of subjects: 24
Study 29635857 — intervention group
Group type: EXPERIMENTAL
Intervention: Δ9-THC (10 mg)
Number of subjects: 24
Study 29635857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 28570127 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine autoinjector
Number of subjects: 189
Study 28570127 — intervention group
Group type: COMPARATOR
Intervention: Manual delivery of epinephrine
Number of subjects: 189
Study 26286324 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitii™ training (20 weeks, 30 min per day, six days a week, total dose of 60 hours)
Number of subjects: 60
Study 26286324 — intervention group
Group type: COMPARATOR
Intervention: Usual care (waitlisted for 20 weeks)
Number of subjects: 60
Study 23816491 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended release gabapentin (G-ER) up to 3000 mg/d
Number of subjects: 120
Study 23816491 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended release gabapentin (G-ER)
Number of subjects: 120
Study 23816491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 21359223 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenitally deaf participants
Number of subjects: 43
Study 21359223 — intervention group
Group type: COMPARATOR
Intervention: Normal-hearing participants
Number of subjects: 43
Study 18842157 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated programme including prehabilitation and early rehabilitation
Number of subjects: 60
Study 18842157 — intervention group
Group type: COMPARATOR
Intervention: Standard care programme
Number of subjects: 60
Study 17312707 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in diagnostic ultrasound systems (UTS) with hands-on scanning practice
Number of subjects: 37
Study 17312707 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic ultrasound images produced by students
Number of subjects: 37
Study 14569044 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight alone
Number of subjects: 96
Study 14569044 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight plus age and gender
Number of subjects: 96
Study 14569044 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight plus height, gender, Tanner stage, and abdominal skinfold
Number of subjects: 96
Study 10965833 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐emptive analgesia with bupivacaine infiltrated preoperatively, intraoperatively, and postoperatively
Number of subjects: 70
Study 10965833 — intervention group
Group type: COMPARATOR
Intervention: Saline infiltrations at the same times
Number of subjects: 70
Study 10765339 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional method (EG)
Number of subjects: 70
Study 10765339 — intervention group
Group type: COMPARATOR
Intervention: Traditional method (CG)
Number of subjects: 70
Study 8347073 — intervention group
Group type: EXPERIMENTAL
Intervention: Autotraction (AT)
Number of subjects: 67
Study 8347073 — intervention group
Group type: COMPARATOR
Intervention: Passive Traction (PT)
Number of subjects: 67
Study 3760276 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical capsaicin applied to one side of the body
Number of subjects: 44
Study 3760276 — intervention group
Group type: COMPARATOR
Intervention: Vehicle applied to the other side of the body
Number of subjects: 44
Study 3760276 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical capsaicin
Number of subjects: 44
Study 3760276 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 44
Study 31828283 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency
Number of subjects: 100
Study 31828283 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25(OH) vitamin D
Number of subjects: 100
Study 28254106 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion
Number of subjects: 0
Study 28254106 — intervention group
Group type: COMPARATOR
Intervention: Moxibustion control or placebo procedure
Number of subjects: 0
Study 23070104 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART stent
Number of subjects: 150
Study 23070104 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty (PTA)
Number of subjects: 150
Study 21784377 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5 mg once-weekly (with titration to 10 mg if not at LDL goal at week 4)
Number of subjects: 17
Study 21784377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 21784377 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 17
Study 19270639 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy plus mesoglycan 50 mg p.o., twice a day
Number of subjects: 44
Study 19270639 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 44
Study 16521017 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline solution containing a low dose of norepinephrine
Number of subjects: 84
Study 16521017 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 84
Study 15187503 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mL/kg predicted body weight tidal volume
Number of subjects: 300